Topic

Articles

Wacker will support production of CureVac’s COVID-19 mRNA-based vaccine candidate at its biotech site in Amsterdam, with production scheduled to start in the first half of 2021.

CureVac and Wacker Sign Manufacturing Contract for COVID-19 Vaccine Candidate

The new super plant, being built in Incheon, South Korea, will have a total biopharmaceutical manufacturing capacity of 256,000 L.

Samsung Biologics Begins Construction on Fourth Biopharma Manufacturing Plant 

The agreement follows a recent announcement that Sartorius plans to invest $100 million in Songdo, South Korea’s bio cluster.

Samsung Biologics Signs MOU with Sartorius to Enhance Supply Chain for Biomedicines

Jill Wechsler is BioPharm International's Washington Editor, jillwechsler7@gmail.com.

The Trump administration unveiled a new drug price control policy, drawing opposition from pharma manufacturers and pharmacy benefit managers.

Trump’s Revenge on Pharma

Bone Therapeutics has reported the completion of Catalent’s acquisition of Skeletal Cell Therapy Support SA (SCTS)—Bone Therapeutics’ cell therapy manufacturing subsidiary.

Catalent Completes Acquisition of Bone Therapeutics’ Cell Therapy Manufacturing Subsidiary

PhoreMost and Oxford Biomedica have entered into a discovery collaboration for the development of next-generation chimeric antigen receptor T-cell therapies.

PhoreMost, Oxford Biomedica Enter Discovery Collaboration for Next-Gen CAR-T Therapies

Kevin E. Noonan, PhD, is a partner at McDonnell Boehnen Hulbert & Berghoff LLP.

Opposition to IP protection for COVID-19 vaccines, therapies, tests and other technologies may only prevent eradication and treatment of the disease.

Protecting Intellectual Property for COVID-19 Innovations

The agreement will provide capacity for the manufacturing of AZD7442, currently being developed for the potential prevention and treatment of COVID-19, at Lonza's Portsmouth, NH site.

Lonza to Manufacture AstraZeneca's COVID-19 Long-Acting Antibody Combination

NanoMab Technology has signed heads of terms with a supplier of Tungsten-188/Rhenium-188 generators, OncoBeta.

NanoMab Technology Signs Heads of Terms with OncoBeta

Recent data, from BIA and Clarivate, has revealed that investment in UK biotech continues to be strong.

BioBusiness